Loomba, Rohit

Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice

Hartmann, P., Hochrath, K., Horvath, A., Chen, P., Seebauer, C. T., Llorente, C., Wang, L., Alnouti, Y., Fouts, D. E., Stärkel, P., et al. (2018) · Hepatology

Gut microbiota and healthAlcohol Consumption and Health Effects

Cited by 290

Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis

Stine, J. G., Munaganuru, N., Barnard, A., Wang, J. L., Kaulback, K., Argo, C. K., Singh, S., Fowler, K. J., Sirlin, C. B., & Loomba, R. (2021) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 283

Mass spectrometry searches using MASST

Wang, M., Jarmusch, A. K., Vargas, F., Aksenov, A. A., Gauglitz, J. M., Weldon, K., Petras, D., da Silva, R., Quinn, R., Melnik, A. V., et al. (2020) · Nature Biotechnology

Metabolomics and Mass Spectrometry StudiesMass Spectrometry Techniques and Applications

Cited by 281

Transforming Growth Factor Beta Signaling in Hepatocytes Participates in Steatohepatitis Through Regulation of Cell Death and Lipid Metabolism in Mice

Yang, L., Roh, Y. S., Song, J., Zhang, B., Liu, C., Loomba, R., & Seki, E. (2014) · Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 275

Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus

Llorente, C., Jepsen, P., Inamine, T., Wang, L., Bluemel, S., Wang, H. J., Loomba, R., Bajaj, J. S., Schubert, M. L., Sikaroodi, M., et al. (2017) · Nature Communications

Gut microbiota and healthAlcohol Consumption and Health Effects

Cited by 257

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

Alkhouri, N., Herring, R., Kabler, H., Kayali, Z., Hassanein, T., Kohli, A., Huss, R. S., Zhu, Y., Billin, A. N., Damgaard, L. H., et al. (2022) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentHepatitis C virus research

Cited by 230

Impact of non-invasive biomarkers on hepatology practice: past, present and future

Anstee, Q. M., Castera, L., & Loomba, R. (2022) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 224

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging

Flint, A., Andersen, G., Hockings, P., Johansson, L., Morsing, A., Sundby Palle, M., Vogl, T., Loomba, R., & Plum‐Mörschel, L. (2021) · Alimentary Pharmacology & Therapeutics

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 224

Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial

Ratziu, V., de Guevara, L., Safadi, R., Poordad, F., Fuster, F., Flores-Figueroa, J., Arrese, M., Fracanzani, A. L., Ben Bashat, D., Lackner, K., et al. (2021) · Nature Medicine

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 222

Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study

Loomba, R., Yang, H.-I., Su, J., Brenner, D., Barrett-Connor, E., Iloeje, U., & Chen, C.-J. (2013) · American Journal of Epidemiology

Alcohol Consumption and Health EffectsHepatocellular Carcinoma Treatment and Prognosis

Cited by 221

TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial

Loomba, R., Mohseni, R., Lucas, K. J., Gutierrez, J. A., Perry, R. G., Trotter, J. F., Rahimi, R. S., Harrison, S. A., Ajmera, V., Wayne, J. D., et al. (2021) · Gastroenterology

Liver Disease Diagnosis and TreatmentCancer, Lipids, and Metabolism

Cited by 220

Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis

Lawitz, E. J., Coste, A., Poordad, F., Alkhouri, N., Loo, N., McColgan, B. J., Tarrant, J. M., Nguyen, T., Han, L., Chung, C., et al. (2018) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentDrug-Induced Hepatotoxicity and Protection

Cited by 217

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease

Nakajima, A., Eguchi, Y., Yoneda, M., Imajo, K., Tamaki, N., Suganami, H., Nojima, T., Tanigawa, R., Iizuka, M., Iida, Y., et al. (2021) · Alimentary Pharmacology & Therapeutics

Liver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated Receptors

Cited by 213

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study

Harrison, S. A., Alkhouri, N., Davison, B. A., Sanyal, A., Edwards, C., Colca, J. R., Lee, B. H., Loomba, R., Cusi, K., Kolterman, O., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 211

Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: analysis of data from a phase II trial of selonsertib

Jayakumar, S., Middleton, M. S., Lawitz, E. J., Mantry, P. S., Caldwell, S. H., Arnold, H., Mae Diehl, A., Ghalib, R., Elkhashab, M., Abdelmalek, M. F., et al. (2019) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentUltrasound Imaging and Elastography

Cited by 208

Link between gut‐microbiome derived metabolite and shared gene‐effects with hepatic steatosis and fibrosis in NAFLD

Caussy, C., Hsu, C., Lo, M., Liu, A., Bettencourt, R., Ajmera, V. H., Bassirian, S., Hooker, J., Sy, E., Richards, L., et al. (2018) · Hepatology

Liver Disease Diagnosis and TreatmentGut microbiota and health

Cited by 205

Collagen biology and non‐invasive biomarkers of liver fibrosis

Karsdal, M. A., Daniels, S. J., Holm Nielsen, S., Bager, C., Rasmussen, D. G. K., Loomba, R., Surabattula, R., Villesen, I. F., Luo, Y., Shevell, D., et al. (2020) · Liver International

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 197

Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease

Sharpton, S. R., Schnabl, B., Knight, R., & Loomba, R. (2021) · Cell Metabolism

Gut microbiota and healthLiver Disease Diagnosis and Treatment

Cited by 194

Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges

Dufour, J.-F., Caussy, C., & Loomba, R. (2020) · Gut

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 193

Effect of Weight Loss on Magnetic Resonance Imaging Estimation of Liver Fat and Volume in Patients With Nonalcoholic Steatohepatitis

Patel, N. S., Doycheva, I., Peterson, M. R., Hooker, J., Kisselva, T., Schnabl, B., Seki, E., Sirlin, C. B., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentAdvanced MRI Techniques and Applications

Cited by 173

Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis

Carlsson, B., Lindén, D., Brolén, G., Liljeblad, M., Bjursell, M., Romeo, S., & Loomba, R. (2020) · Alimentary Pharmacology & Therapeutics

Liver Disease Diagnosis and TreatmentNutrition, Genetics, and Disease

Cited by 169

Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study

Rinella, M. E., Dufour, J.-F., Anstee, Q. M., Goodman, Z., Younossi, Z., Harrison, S. A., Loomba, R., Sanyal, A. J., Bonacci, M., Trylesinski, A., et al. (2022) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 164

Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges

Kokkorakis, M., Boutari, C., Hill, M. A., Kotsis, V., Loomba, R., Sanyal, A. J., & Mantzoros, C. S. (2024) · Metabolism

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 155

Risk assessment with gut microbiome and metabolite markers in NAFLD development

Leung, H., Long, X., Ni, Y., Qian, L., Nychas, E., Siliceo, S. L., Pohl, D., Hanhineva, K., Liu, Y., Xu, A., et al. (2022) · Science Translational Medicine

Gut microbiota and healthLiver Disease Diagnosis and Treatment

Cited by 152